Staff Clinician
NIH/NIDCR
Building 30, Room 228
30 Convent Dr. MSC 4320
Bethesda, MD 20892-4320
United States
Dr. Kelly Lauter Roszko’s research interests center around disorders of mineral homeostasis which include diseases of altered FGF23 metabolism and hypoparathyroidism. Her main focus is hyperphosphatemic familial tumoral calcinosis, a disease of FGF23 deficiency resulting in high serum phosphate levels and ectopic calcification. She studies patients with this disease and uses a mouse model to expand understanding of the phenotype, mechanism of disease, and treatment options. She has published numerous manuscripts including those focused on Autosomal Dominant Hypocalcemia (ADH) Type 1 and 2; and she is an investigator on the trials of Encaleret, a calcilytic medication for targeted therapy of ADH1. As a physician-scientist, she is pursuing projects in the basic science and in translational medicine with the goal of bringing new treatments to patients with rare diseases of mineral metabolism.
Dr. Kelly Roszko is an Adult Endocrinologist at the National Institutes of Health. Her interest in bone and mineral metabolism began during her M.D., Ph.D. training at the University of Connecticut. She initially studied hyperparathyroidism and completed her Ph.D. dissertation under the mentorship of Dr. Andrew Arnold, M.D. She then completed internship and residency in Internal Medicine as well as fellowship in Endocrinology at the Massachusetts General Hospital/Harvard Medical School in Boston. There, with the mentorship of Dr. Michael Mannstadt, she focused on Autosomal Dominant Hypocalcemia Type 2 (ADH2), creating a mouse model of the disease and testing treatments. After her fellowship, she joined the faculty at Massachusetts General Hospital before moving to NIH. She is now working in NIDCR’s Skeletal Disorders and Mineral Homeostasis Section, led by Dr. Michael Collins.